Altamira Therapeutics Ltd., a company committed to developing therapeutics that address unmet medical needs, announced that Bentrio™ has been approved by the Philippines’ Food and Drug Administration (FDA) and is now cleared for commercialization.

The product will be commercialized through the local affiliate of Wellesta Holdings Pte Ltd, Singapore. Prior to approval for commercialization, there was a marketing and distribution agreement with Altamira which included the Philippines in February. Wellesta will commercialize and distribute Bentrio in India, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Vietnam and Morocco (the “Territory”). Within that Territory, Bentrio previously received approval in Singapore and Malaysia.

Last week, the Company reported positive data from its house dust mite (HDM) challenge clinical trial. The trial was conducted in Canada and the results displayed a significant reduction of nasal symptoms vs. untreated controls as well as product safety. HDM allergens embody the prime cause of respiratory allergies such as allergic rhinitis and allergic asthma. HDMs may be present all year long in contrast to plant-related allergens, which tend to be seasonal (pollen/hay fever).

Read more here